RxDoctor Payments Data

Apryl Butler, APRN

Nurse Practitioner · Frankfort, KYNPI 1962007922

Payments from drug & device makers

$2,569in general payments, 2019–2025

Across 148 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$971
  • Lilly USA, LLC$250
  • Novo Nordisk$234
  • Teva Pharmaceuticals USA, Inc.$186
  • Vanda Pharmaceuticals Inc.$151
  • Johnson & Johnson$132
  • plus $644 from 14 others

What the payments were for

  • Food & beverage$2,53699%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,569 in reported general payments places this provider in the 80th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$986
Medicare patients
21
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$82,750
OtezlaApremilast13$59,725
JardianceEmpagliflozin26$43,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$41,473
MounjaroTirzepatide41$39,329
VraylarCariprazine Hcl23$35,230
TrulicityDulaglutide17$29,810
EliquisApixaban22$23,636
JanuviaSitagliptin Phosphate19$21,160
Spiriva HandihalerTiotropium Bromide18$15,915
FarxigaDapagliflozin Propanediol12$14,552
TradjentaLinagliptin19$13,391
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$12,098
JanumetSitagliptin Phos/Metformin Hcl14$7,020
SavellaMilnacipran Hcl11$5,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$234$82,75078 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$250$69,77579 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$14$69,22657 claims
AmgenOtezla$62$59,72513 claims
GSKTrelegy Ellipta$83$41,47354 claims
AbbVieVraylar, Savella, Synthroid$971$41,31750 claims
PfizerEliquis$78$23,63622 claims
AstraZenecaFarxiga$16$14,55212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Frankfort

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →